[
  {
    "ts": "2025-12-08T06:30:00+00:00",
    "headline": "OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development",
    "summary": "OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development Strategic Amendment Enhances OSE Immunotherapeutics’ Role in ABBV-230 Development While Preserving AbbVie’s Long-Term Commitment NANTES, France, December 8th, 2025 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced an amendment to its partnership agreement with AbbVie regarding ABBV-230, a monoclonal antibody designed to resolve chronic and severe inflammati",
    "url": "https://finance.yahoo.com/news/ose-immunotherapeutics-announces-strategic-amendment-063000041.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "98812cad-0b21-3dcd-8443-fa28548bb85f",
      "content": {
        "id": "98812cad-0b21-3dcd-8443-fa28548bb85f",
        "contentType": "STORY",
        "title": "OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development",
        "description": "",
        "summary": "OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development Strategic Amendment Enhances OSE Immunotherapeutics’ Role in ABBV-230 Development While Preserving AbbVie’s Long-Term Commitment NANTES, France, December 8th, 2025 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced an amendment to its partnership agreement with AbbVie regarding ABBV-230, a monoclonal antibody designed to resolve chronic and severe inflammati",
        "pubDate": "2025-12-08T06:30:00Z",
        "displayTime": "2025-12-08T06:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/30f72419d0291606fc6eb96fa53d5067",
          "originalWidth": 3189,
          "originalHeight": 1063,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G57RQkdfRqxD8fSqS10JEQ--~B/aD0xMDYzO3c9MzE4OTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/30f72419d0291606fc6eb96fa53d5067.cf.webp",
              "width": 3189,
              "height": 1063,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CMuCyX2VYx6bKd3LOJUC.A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/30f72419d0291606fc6eb96fa53d5067.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ose-immunotherapeutics-announces-strategic-amendment-063000041.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ose-immunotherapeutics-announces-strategic-amendment-063000041.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "OSE.PA"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]